18 results about "Hormone therapy" patented technology

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and one or more AP electromagnetic coil adapted to be coupled to at least a portion of a patient's body, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 KHz and a field strength of 0.5-5 mT to the at least a portion of the patient's body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer therapy such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, an angiogenesis inhibitor drug, or tumor treatment field therapy.

Methods for treating hormonally driven disorders by administering the PI3K / mT0R inhibitor gedatolisib in combination with hormone therapy are provided. Hormonally driven disorders include, for example, prostate cancer and endometrial disorders. The treatment regimens can also include additional therapies, such as chemotherapy, surgery and / or administration of an immune checkpoint inhibitor(s), a receptor tyrosine kinase inhibitor, a CDK 4 / 6 inhibitor or an epigenetic-targeted therapy.

The application relates to the technical field of composite phase change materials, and discloses a halloysite / carbon black aerogel encapsulated paraffin composite phase change material as well as a preparation method and application thereof. Sodium alginate is dissolved in deionized water, halloysite nanotubes and carbon black are added after stirring and dissolving, pyrrole is added after uniform mixing, and stirring is conducted; then, an initiator is added to initiate polymerization to form a hydrogel; the obtained hydrogel is directionally frozen by liquid nitrogen and then freeze-dried to obtain HCSA aerogel; the HCSA aerogel is immersed in molten paraffin to encapsulate paraffin, and the halloysite / carbon black aerogel encapsulated paraffin composite phase change material is obtained. The HCSA aerogel forms a stable three-dimensional porous structure by virtue of multi-component synergistic effect, the compressive strength is significantly improved, and the encapsulation rate of the PW is significantly improved; the PW@HCSA has excellent shape stability and thermal stability, and meets the long-term use requirement of thermal energy storage.

The invention discloses an application of harpagide in preparation of a medicine for inhibiting STUB1. The harpagide can be used as a specific inhibitor of E3 ubiquitin ligase STUB1. By inhibiting the STUB1, the harpagide can effectively block the GR ubiquitination process mediated by the STUB1, so that the GR is prevented from being degraded by the proteasome, and the stability of the GR protein level is finally realized. Through combined application of harpagide and glucocorticoid, the treatment effect of hormone in a noise-induced hearing loss animal model can be remarkably improved, and the treatment effect is better than that of treatment by independently using hormone.

This invention relates to the field of biomedical technology and proposes a biomarker for reflecting the efficacy of hormone therapy for allergic rhinitis and its application. The biomarker includes one or more combinations of IFNGR1, Furin, and CSF1R. The biomarkers IFNGR1, Furin, and CSF1R of this invention can all differentiate between hormone-sensitive and hormone-insensitive rhinitis. Their expression levels in the nasal secretions of patients with hormone-insensitive allergic rhinitis are significantly lower than those of patients with hormone-sensitive allergic rhinitis, thus reflecting the efficacy of hormone therapy for allergic rhinitis. Furthermore, compared with a single biomarker, the combination of the three biomarkers has better discriminative ability and better efficacy, providing important evidence for subsequent treatment of allergic rhinitis.

Acute exposure to estrogenic chemicals is shown herein to induce DNA damage mediated by formation of ERα-dependent R-loops. Disclosed herein are methods for evaluating the safety and activity of a xenoestrogen. Also disclosed are methods for identifying subject particularly susceptible to the genotoxic effects of endogenous estrogens or environmental xenoestrogens. This method can be used to select suitable hormone therapies, such as a selective estrogen receptor modulator (SERM), aromatase inhibitor, or selective estrogen receptor degrader (SERD).

This invention discloses an in vivo sperm processing device, control method, and application based on surface acoustic wave (SAW) devices. The non-invasive in vivo sperm processing method based on SAW devices offers significant advantages: it avoids the trauma risks of surgical and acupuncture treatments and solves the problem of unstable effects from hormone therapy and antioxidant therapy. By precisely controlling SAW parameters, this invention significantly improves sperm motility. It is simple to operate, low in cost, and highly safe, and applicable to various types of oligospermia and asthenospermia, providing a highly efficient, non-invasive, and widely applicable new solution for the research and treatment of oligospermia and asthenospermia.

An injector pump having a fluid reservoir sealed to a length of tubing extending from the reservoir and an automatic needle injection mechanism. The fluid hormone is delivered over a continuous, extended period to provide for the delivery of replacement hormones based on the hormone fluctuations of the patient and naturally occurring hormone cycles.

Methods for treating hormonally driven disorders by administering the PI3K / mTOR inhibitor gedatolisib in combination with hormone therapy are provided. Hormonally driven disorders include, for example, prostate cancer and endometrial disorders. The treatment regimens can also include additional therapies, such as chemotherapy, surgery and / or administration of an immune checkpoint inhibitor(s), a receptor tyrosine kinase inhibitor, a CDK 4 / 6 inhibitor or an epigenetic-targeted therapy.

This invention relates to the field of biomedical technology and proposes RBP4 and Ferritin as biomarkers for evaluating the efficacy of hormone therapy for allergic rhinitis. The biomarkers include one or a combination of RBP4 and Ferritin. Studies have confirmed that both RBP4 and Ferritin are capable of distinguishing between hormone-sensitive and hormone-insensitive allergic rhinitis. RBP4 is expressed at higher levels in the hormone-sensitive allergic rhinitis group, while Ferritin is expressed at higher levels in the hormone-insensitive allergic rhinitis group. Compared to single biomarker detection, the combined use of RBP4 and Ferritin significantly improves the differential diagnostic efficacy, providing better differentiation between the two patient groups.

The present invention provides a method for detecting and characterizing a mouse model of stem cell lineage plasticity characterized by (i) levels of sirtuin (SIRT3) protein below a first predetermined threshold, (ii) levels of manganese superoxide dismutase acetylated at lysine 68 (AcK68) above a second predetermined threshold, and (iii) levels of hypoxia-inducible factor 2 (HIF2) above a third predetermined threshold, which are indicative of stemness and lineage plasticity. α (HIF2 α and optionally administering an additional anti-cancer therapeutic agent, said method comprising administering to said mammalian subject a therapeutically effective amount of a pentaaza macrocyclic ring complex corresponding to formula (I):

This invention relates to the field of biomedical technology and proposes a biomarker for evaluating the efficacy of hormone therapy for allergic rhinitis and its application. The biomarker includes one or a combination of TFF3 and WFDC2. Both TFF3 and WFDC2 can differentiate between hormone-sensitive and hormone-insensitive rhinitis. Compared to a single biomarker, the combined use of the two significantly improves the differentiation efficacy and provides better differentiation between the two types of patients.

The present invention relates to a method for producing a liposomal preparation by emulsification, the preparation containing liposomes with encapsulated hormones, comprising: a first emulsification step of emulsifying a first composition, the first composition comprising water, propylene glycol, an emulsifier and a hormone to be encapsulated; characterized in that for the emulsification of the first emulsification step, a rotor-stator emulsifier is used, which is provided with a stator with perforations with a diameter between 0.8 and 5 mm, and wherein the rotational speed is at least 6000 rpm. The invention also relates to a liposomal preparation comprising liposomes with encapsulated hormones or esters thereof, and a liposomal preparation for use in hormone therapy or for use in the treatment of hypogonadism and / or adrenal insufficiency.

The present disclosure is directed to a triplex immunohistochemical assay for detecting the colocalization of the ER, PR, and Ki-67 biomarkers in cells or cell nuclei. It is believed that the brightfield triplex immunohistochemical assay of the present disclosure may serve as a prognostic assay for ER-positive breast cancer, facilitating the identification of disease-free survivors among ER-positive breast cancer patients treated with hormone therapy.

The object of the present invention is to provide a therapeutic agent for treating hormone therapy-resistant, treatment-resistant cancers, and a method of the treatment of hormone therapy-resistant, treatment-resistant cancers. The problem can be solved by a pharmaceutical composition including a compound represented by the formula (1) or a salt thereof or a compound represented by the formula (2) or (3) or a salt thereof, as an active ingredient for treating prostate cancer. Furthermore, the pharmaceutical composition of the present invention can effectively treat not only hormone therapy-resistant prostate cancer or breast cancer but also non-hormone therapy-resistant prostate cancer or breast cancer and Castration-resistant prostate cancer or treatment-resistant breast cancer caused by other mechanisms.

The invention provides optimized upstream processes for the production of recombinant gonadotropins including corifollitropin alfa (CFA), recombinant human chorionic gonadotropin (r-hCG), and recombinant human follicle- stimulating hormone (r-hFSH) in mammalian cell culture. The processes comprise revival of CHO cells from cryopreservation, expansion in shake flasks, seed generation in wave bioreactors, and production in stirred-tank bioreactors operated in fed-batch mode. Defined media supplemented with additives such as N-acetyl mannosamine, or stabilized glutamine enhance cell viability, productivity, and glycosylation quality. Cultures are terminated at defined viability thresholds or timepoints, and clarified by sequential depth and membrane filtration. The methods offer scalability, reproducibility, and superior product quality compared to conventional approaches, enabling consistent large-scale manufacture of therapeutic gonadotropins for fertility treatments and hormone therapies.

The present disclosure relates to a triple immunohistochemical assay for detecting co-localization of ER, PR and Ki-67 biomarkers in a cell or nucleus. It is believed that the bright field triple immunohistochemistry assay of the present disclosure can be used as a prognostic assay for ER-positive breast cancer, facilitating the identification of disease-free survivors in ER-positive breast cancer patients treated with hormone therapy.